Aptamer Group plc (AIM: APTA), the York-based developer of next-generation synthetic Optimer® binders, has announced immediate changes to its Board and senior leadership team as it accelerates its proprietary therapeutic programmes. Dr Paloma Giangrande, an RNA therapeutics specialist previously at Orbital Therapeutics — whose discovery platform was acquired by Bristol Myers Squibb in December 2025 for US$1.5 billion — joins as a Non-Executive Director. Dr James McNamara is simultaneously appointed Head of Oligonucleotide Therapeutic Development, while co-founder Dr David Bunka steps down from the Board to focus exclusively on research and development. The changes align with the strategic plan the company set out in March 2026 to build a proprietary therapeutic business alongside its existing fee-for-service discovery operations.

Key Points

  • Aptamer Group plc (AIM: APTA) — York-based developer of synthetic Optimer® binders and oligonucleotide therapeutics
  • Dr Paloma Giangrande joins the Board as Non-Executive Director effective immediately, bringing senior RNA therapeutics and delivery expertise
  • Dr James McNamara appointed Head of Oligonucleotide Therapeutic Development; co-founder Dr David Bunka steps down from the Board but remains as Head of R&D
  • Investors may be watching for data updates from the ongoing in vivo Optimer®-targeted radiotherapy study and oligonucleotide delivery programmes

Dr Paloma Giangrande Brings RNA Delivery and Clinical Translation Experience to Aptamer's Board

Dr Giangrande, aged 54, is an internationally recognised expert in nucleic acid therapeutics. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver at the University of Iowa and subsequently held senior roles at Moderna, Wave Life Sciences — where she took an RNA editing programme into first-in-human studies — and Eleven Therapeutics, where she served as Chief Technology Officer. Most recently, she was Senior Vice President of Discovery and Translational Biology at Orbital Therapeutics, overseeing the platform acquired by Bristol Myers Squibb in December 2025 for US$1.5 billion. She has served on Aptamer's Scientific Advisory Board since December 2024 and will continue in that role alongside her Board position.

Dr James McNamara to Lead Oligonucleotide Therapeutic Programmes Funded in March 2026

Dr McNamara's appointment as Head of Oligonucleotide Therapeutic Development adds further scientific depth to Aptamer's internal pipeline. Working alongside Dr Giangrande at Duke University, he co-developed one of the first methods for using aptamers to deliver siRNA to specific cell types — the foundational approach underpinning Aptamer's targeted delivery programmes. He brings additional experience as Associate Professor of Internal Medicine at the University of Iowa and as founder and Chief Executive Officer of Nuclease Probe Technologies, Inc. He will report directly to Chief Executive Officer Dr Arron Tolley and lead the in vivo oligonucleotide delivery studies funded as part of the March 2026 strategic plan.

Co-Founder Dr David Bunka Steps Down from Board to Focus on Automated Optimer® Platform Development

Dr David Bunka, who co-founded Aptamer with Dr Tolley in 2008 and has served as a Director since the company's foundation, has stepped down from the Board with immediate effect. The announcement states he made this decision to concentrate fully on leading the continuous improvement of the Group's automated Optimer® selection platforms. The high-throughput data generated by these platforms supports Aptamer's fee-for-service business, therapeutic lead candidate generation, and its AI-enabled discovery engine. The company's AI and machine learning build was reportedly completed six months ahead of schedule, according to the CEO's comments included in the announcement.

Aptamer's Dual-Revenue Model and In Vivo Study Progress Frame the Strategic Context

Aptamer operates a dual-revenue model, generating near-term income through fee-for-service discovery programmes while building proprietary therapeutic assets intended to generate long-term value via licensing, royalties, and supply agreements. The Group's first in vivo study, in Optimer®-targeted radiotherapy, is currently underway and is led by Dr Louis Allott, Director of Radioligand Development. The company's strategic focus centres on two significant drug development challenges: targeting undruggable proteins and enabling therapeutic delivery to tissues beyond the liver. Investors may be watching for data disclosures from these in vivo studies as Aptamer seeks to attract pharmaceutical partners to its proprietary pipeline.